- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03595813
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy (IMMUNO-SUP)
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002
The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood.
In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Bouches-du-Rhône
-
Marseille, Bouches-du-Rhône, France
- Institut Paoli-Calmettes
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- Diagnosis of locally advanced or metastatic solid tumor or lymphoma treated with Immune check blockade
- Signed informed consent
- Affiliated to(or beneficiary of) the French Social Security
Exclusion Criteria:
- Pregnant or breastfeeding woman or woman who does not apply effective contraception
- Emergency
- Vulnerable person or unable to provide informed consent
- Emergency
- Person unable to comply with required study follow up
- Contraindication to the study procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients treated with Immune Checkpoint Blockade
|
Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
Optional biopsy collection at baseline and progression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Plasma immunosuppressive actors in patients treated with a Checkpoint inhibitor
Time Frame: 4 months
|
Measure (by flux cytometry) and comparison of plasma immunosuppressive actors, between baseline and the 4th injection of an Immune Checkpoint inhibitor
|
4 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMMUNO-SUP-IPC 2017-002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urologic Neoplasms
-
University Hospital, GhentCompletedSurgery | Bladder Cancer | Urologic CancerBelgium
-
The Catholic University of KoreaActive, not recruitingUrologic CancerKorea, Republic of
-
Exosome Diagnostics, Inc.CompletedUrologic CancerUnited States, Germany
-
Fox Chase Cancer CenterBristol-Myers SquibbCompletedUrologic NeoplasmUnited States
-
Ricardo RendonTerminatedKidney NeoplasmsCanada
-
M.D. Anderson Cancer CenterUnknown
-
Urological Research Network, LLCRecruitingKidney NeoplasmsUnited States
-
Lindis Biotech GmbHRecruitingUrinary Bladder NeoplasmsGermany
-
Association of Urologic Oncology (AUO)IAG-N at German Cancer Association (Deutsche Krebsgesellschaft e. V.)Not yet recruiting
Clinical Trials on Blood sample collection
-
Poitiers University HospitalRecruitingPsoriasis | Psoriatic ArthritisFrance
-
Institut PasteurCentre Médical de l'Institut PasteurRecruiting
-
Emory UniversityMichael J. Fox Foundation for Parkinson's ResearchCompletedDefining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative ProcessesParkinson's DiseaseUnited States
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Leukemia | Chemotherapy-Induced Gut Barrier DamageUnited States
-
Rennes University HospitalCompletedHistory of Exposure to Silica or Asbestosis | Positive Testing for ANA as a Marker of Systemic Autoimmune DiseasesFrance
-
Masonic Cancer Center, University of MinnesotaCompletedAcute Myeloid LeukemiaUnited States
-
Benjamin GesundheitShaare Zedek Medical CenterRecruiting
-
Thomas Jefferson UniversityRecruitingBreast Cancer | Invasive Breast Cancer | Carcinoma in Situ of the BreastUnited States